Craig Tuttle - Chief Executive Officer, President
Craig J. Tuttle has served as President and Chief Executive Officer of Transgenomic since July 2006. Mr. Tuttle was previously the President and COO of Duke Scientific, a specialty particle technology company, and before that he was the President and CEO of Applied Biotech, Inc, a leading point-of-care rapid diagnostics manufacturer in the Apogent Technologies group. He has held management positions at Seradyn, Boehringer Mannheim, Difco Laboratories and Cetus Corporation. Mr. Tuttle holds a B.S. degree in Biochemistry from UCLA, an M.S. degree in Biochemistry from the University of Colorado, and an MBA from St. Mary’s College.
Chad Richards - Chief Commercial Officer
Mr. Richards joined Transgenomic in October 2007 as Senior Vice President, Sales and Marketing. Mr. Richards brings 14 years of sales and marketing experience in laboratory services and diagnostics. Before joining Trangenomic, Mr. Richards was the National Sales Director for Anatomic Pathology for Quest Diagnostics, the world’s largest laboratory service business. During his career with Quest Diagnostics, Mr. Richards held a variety of sales management roles in both their physician and hospital business segments. Before joining Quest Diagnostics, Mr. Richards held different marketing and sales management roles with Ventana Medical Systems, a world leader in developing and manufacturing immunohistochemistry and in-situ hybridization instruments and reagent systems. Mr. Richards holds a B.S. degree in Biology from the University of Minnesota.
Mark Colonnese - Chief Financial Officer
Mr. Colonnese has nearly 30 years of experience in leading business growth and financial strategies for life sciences companies. He most recently served as Executive Vice President, Commercial Operations and Chief Financial Officer at Salutria Pharmaceuticals, LLC, a privately-held, development-stage pharmaceutical company. Prior to that, Mr. Colonnese served as Executive Vice President, Commercial Operations at AtheroGenics, Inc., a development-stage pharmaceutical company, where he raised $450 million in debt and equity capital, led the company’s IPO in 2000 and helped negotiate a worldwide partnership agreement with AstraZeneca. Prior to joining AtheroGenics, Mr. Colonnese served as Senior Vice President and Chief Financial Officer at Medaphis Corporation and has also held executive positions at Applied Analytical Industries, Inc. and Schering-Plough Corporation. Mr. Colonnese holds an M.B.A. from Fairleigh Dickinson University, a B.S. magna cum laude from Ithaca College, and is a Certified Public Accountant.
Katrina Fahlin - Vice President of Quality
Katrina Fahlin is the Vice President of Quality for Transgenomic. She holds a B.S. degree in Professional Chemistry from South Dakota State University and has graduate work in chemistry from the University of Nebraska. Ms. Fahlin has more than 30 years of experience in the quality arena including thirteen years with Novartis in Quality Assurance. She is a qualified Lead Auditor and her regulatory experience includes ISO standards, and FDA experience with pharmaceuticals, feed, food, and food and feed additives. She has lead the successful efforts at Transgenomic to attain ISO 9001 certification for their instrument and bioconsumable business and the College of American Pathologist accreditation of the CLIA reference laboratory.
Katherine A. Richardson, Ph. D. - Vice President of Research and Development
Dr. Richardson is Vice President of Research and Development. She holds an S.B. degree in life sciences from the Massachusetts Institute of Technology and a Ph.D. in molecular cellular developmental biology from Iowa State University. Dr. Richardson has more than 25 years of molecular biology laboratory experience. She joins Transgenomic following eight years as a scientist with OSI Pharmaceuticals, where she specialized in molecular biology research and development in the area of oncology. Previously Dr. Richardson was with Eli Lilly and Company for nine years as a senior toxicologist specializing in genetic toxicology and molecular carcinogenesis. Dr. Richardson has to her credit nearly 60 publications, abstracts and presentations at scientific conferences, and she was part of the group at Eli Lilly that identified the link between the BRCA-1 gene and hereditary breast cancer.